353 related articles for article (PubMed ID: 31354708)
1. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
Front Immunol; 2019; 10():1527. PubMed ID: 31354708
[No Abstract] [Full Text] [Related]
2. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
3. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).
Ramos-Casals M; Brito-Zerón P; Solans R; Camps MT; Casanovas A; Sopeña B; Díaz-López B; Rascón FJ; Qanneta R; Fraile G; Pérez-Alvarez R; Callejas JL; Ripoll M; Pinilla B; Akasbi M; Fonseca E; Canora J; Nadal ME; de la Red G; Fernández-Regal I; Jiménez-Heredia I; Bosch JA; Ayala MD; Morera-Morales L; Maure B; Mera A; Ramentol M; Retamozo S; Kostov B; ;
Rheumatology (Oxford); 2014 Feb; 53(2):321-31. PubMed ID: 24162151
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
[TBL] [Abstract][Full Text] [Related]
5. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E
Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
[TBL] [Abstract][Full Text] [Related]
6. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
Demarchi J; Papasidero S; Medina MA; Klajn D; Chaparro Del Moral R; Rillo O; Martiré V; Crespo G; Secco A; Catalan Pellet A; Amitrano C; Crow C; Asnal C; Pucci P; Caeiro F; Benzanquen N; Pirola JP; Mayer M; Zazzetti F; Velez S; Barreira J; Tamborenea N; Santiago L; Raiti L
Clin Rheumatol; 2017 Nov; 36(11):2455-2460. PubMed ID: 28913747
[TBL] [Abstract][Full Text] [Related]
7. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
8. Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome.
Moerman RV; Arends S; Meiners PM; Vissink A; Spijkervet FK; Kroese FG; Brouwer E; Bootsma H
J Rheumatol; 2017 Mar; 44(3):292-296. PubMed ID: 28089983
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
[TBL] [Abstract][Full Text] [Related]
10. Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.
Iwata N; Tomiita M; Kobayashi I; Inoue Y; Nonaka Y; Okamoto N; Umebayashi H; Hara R; Ito Y; Sato Y; Mori M
Pediatr Rheumatol Online J; 2020 Sep; 18(1):73. PubMed ID: 32943063
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
12. Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients.
Fauchais AL; Ouattara B; Gondran G; Lalloué F; Petit D; Ly K; Lambert M; Launay D; Loustaud-Ratti V; Bezanahari H; Liozon E; Hachulla E; Jauberteau MO; Vidal E; Hatron PY
Rheumatology (Oxford); 2010 Jun; 49(6):1164-72. PubMed ID: 20299380
[TBL] [Abstract][Full Text] [Related]
13. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
14. ESSDAI activity index of the SJÖGRENSER cohort: analysis and comparison with other European cohorts.
Rosas J; Sánchez-Piedra C; Fernández-Castro M; Andreu JL; Martínez-Taboada V; Olivé A;
Rheumatol Int; 2019 Jun; 39(6):991-999. PubMed ID: 30891620
[TBL] [Abstract][Full Text] [Related]
15. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
[TBL] [Abstract][Full Text] [Related]
16. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
[TBL] [Abstract][Full Text] [Related]
17. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
Milic V; Colic J; Cirkovic A; Stanojlovic S; Damjanov N
PLoS One; 2019; 14(12):e0226498. PubMed ID: 31891590
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
Shao Q; Jin L; Li C; Wang J; Wang M; Wang Q; Wu B
Explore (NY); 2022; 18(4):416-422. PubMed ID: 34417112
[TBL] [Abstract][Full Text] [Related]
19. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.
Seror R; Ravaud P; Bowman SJ; Baron G; Tzioufas A; Theander E; Gottenberg JE; Bootsma H; Mariette X; Vitali C;
Ann Rheum Dis; 2010 Jun; 69(6):1103-9. PubMed ID: 19561361
[TBL] [Abstract][Full Text] [Related]
20. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
